Generic drug makers will be uniquely vulnerable if the Trump administration rolls out pharmaceutical tariffs, thanks to just how “little resilience” the industry enjoys compared to its patented counterpart, CEO of the United States Pharmacopeia, Ronald Piervincenzi, said in an
read moreGilead Sciences and Sophia Forum, a London-based charity, have launched a campaign to improve HIV care and outreach for women in the U.K.—a group that, according to the partners, has long been overlooked in the nation’s response to the epidemic.
read more
The university has been awarded a £1m grant from LifeArc and Muscular Dystrophy UK More: UCL researchers launch congenital muscular dystrophy research programme Source: News
read moreAkeso and Summit Therapeutics’ PD-1/VEGF bispecific antibody ivonescimab has posted another phase 3 trial win in lung cancer, this time as part of a chemotherapy combination. More: With new trial win, Akeso bispecific shows prior success against Keytruda is no
read moreCEOs from European drugmakers Sanofi and Novartis have inked a letter in The Financial Times urging the European Union to set drug prices relative to those in the U.S., among other measures. The chief executives argued that the move is
read morePaul Reider has followed Coherus BioSciences’ last biosimilar product out the door. As the biotech completes its pivot from biosimilars to novel immuno-oncology programs, Reider has resigned as chief commercial officer to pursue other opportunities. More: Coherus loses commercial chief
read more© 1994 - 2025 B.M. Pharmaceuticals